Trial · NCT07126262
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events | From baseline to end of treatment at 52 weeks | |
| Primary | Incidence of serious adverse events versus placebo over the course of the study | From baseline to end of treatment at 52 weeks | |
| Primary | Changes from baseline in standard clinical laboratory values (hematology, urinalysis, and chemistry) | At week 26, at week 52 | |
| Primary | Changes from baseline in heart rate | At week 13, at week 26, at week 39, at week 52 | Units of measure: bpm |
| Primary | Change from baseline in height Z-score | At week 52 | |
| Primary | Changes from baseline in respiratory rate | At week 13, at week 26, at week 39, at week 52 | Units of measure: breaths/min |
| Primary | Changes from baseline in temperature | At week 13, at week 26, at week 39, at week 52 | Units of measure: celsius |
| Primary | Changes from baseline in blood pressure | At week 13, at week 26, at week 39, at week 52 | Units of measure: mmHg |
| Secondary | Change in height | At week 52 | |
| Secondary | Cumulative annualized growth velocity (AGV) | At week 52 | |
| Secondary | 6-month interval AGV | At week 26, at week 52 | |
| Secondary | Change from baseline in upper to lower body segment ratio | At week 52 | |
| Secondary | Change from baseline in arm span | At week 52 | |
| Secondary | Change from baseline in total body (less head) bone mineral density (BMD) Z-score | At week 52 | |
| Secondary | Change from baseline in lumbar spine BMD Z-score | At week 52 | |
| Secondary | Change from baseline in total body (less head) bone mineral content (BMC) as measured by DXA | At week 52 | |
| Secondary | Change from baseline in lumbar spine BMC as measured by DXA | At week 52 | |
| Secondary | Area under the plasma vosoritide concentration time-curve from time 0 to infinity (AUC0-∞) | At week 26, at week 52 | |
| Secondary | Area under the plasma vosoritide concentration time-curve from time 0 to the last measurable concentration (AUC0-t) | At week 26, at week 52 | |
| Secondary | Elimination half-life of vosoritide (t½) | At week 26, at week 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07126262/registered